Evidence map›Paper›PMID 41340396›Full record

ArticleJMIR AI2025

Machine Learning-Enhanced Quantitative Structure-Activity Relationship Modeling for DNA Polymerase Inhibitor Discovery: Algorithm Development and Validation.

Samuel Kakraba, Srinivas Ayyadevara, Aayire Yadem Clement, Kuukua Egyinba Abraham, Cesar M Compadre, Robert J Shmookler Reis

Abstract read
In one paragraph

Article in JMIR AI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samuel KakrabaDepartment of Biostatistics and Data Science, Celia Scott Weatherhead School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, New Orleans, LA, 70112, United States, 1 5049882475.ORCID http://orcid.org/0000-0002-6362-5126
Srinivas AyyadevaraDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, United States.ORCID http://orcid.org/0000-0002-4572-6361
Aayire Yadem ClementCytoAstra LLC, Little Rock, AR, United States.ORCID http://orcid.org/0000-0002-4923-7792
Kuukua Egyinba AbrahamDepartment of Mathematics, Memphis Shelby County Schools, Memphis, TN, United States.ORCID http://orcid.org/0009-0002-9269-2536
Cesar M CompadreDepartment of Pharmaceutical Sciences, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, United States.ORCID http://orcid.org/0000-0002-5652-0203
Robert J Shmookler ReisDepartment of Pharmaceutical Sciences, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, United States.ORCID http://orcid.org/0000-0002-4691-0734

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett · 2012 to 2026
$60.9M
THE APOE-APP AXIS IN ALZHEIMER PATHOGENESISP01AG012411 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI GRIFFIN, SUE TILTON · 1995 to 2020
$25.0M
BLRD VA I01 BX001655NIA NIH HHS P01 AG012411NIGMS NIH HHS P20 GM103429
6 · The paper itself

Abstract

Background: Cisplatin resistance remains a significant obstacle in cancer therapy, frequently driven by translesion DNA synthesis mechanisms that use specialized polymerases such as human DNA polymerase η (hpol η). Although small-molecule inhibitors such as PNR-7-02 have demonstrated potential in disrupting hpol η activity, current compounds often lack sufficient potency and specificity to effectively combat chemoresistance. The vastness of chemical space further limits traditional drug discovery approaches, underscoring the need for advanced computational strategies such as machine learning (ML)-enhanced quantitative structure-activity relationship (QSAR) modeling. Objective: This study aimed to develop and validate ML-augmented QSAR models to accurately predict hpol η inhibition by indole thio-barbituric acid analogs, with the goal of accelerating the discovery of potent and selective inhibitors that could overcome cisplatin resistance. Methods: A curated library of 85 indole thio-barbituric acid analogs with validated hpol η inhibition data was used, excluding outliers to ensure data integrity. Molecular descriptors spanning 1D to 4D were computed in MAESTRO, resulting in 220 features. In total, 17 ML algorithms, including random forest, extreme gradient boosting (XGBoost), and neural networks, were trained using 80% of the data for training and evaluated with 14 performance metrics. Robustness was ensured through hyperparameter optimization and 5-fold cross-validation. Results: Ensemble methods outperformed other algorithms, with random forest achieving near-perfect predictive performance (training mean square error=0.0002; R²=0.9999 and testing mean square error=0.0003; R²=0.9998). Shapley additive explanations analysis revealed that electronic properties, lipophilicity, and topological atomic distances were the most important predictors of hpol η inhibition. Linear models exhibited higher error rates, highlighting the nonlinear relationship between molecular descriptors and inhibitory activity. Conclusions: Integrating ML with QSAR modeling provides a robust framework for optimizing hpol η inhibition, offering both high predictive accuracy and biochemical interpretability. This approach accelerates the identification of potent selective inhibitors and represents a promising strategy for overcoming cisplatin resistance, thereby advancing precision oncology.

Indexed as

AIartificial intelligencecisplatin resistanceDNA polymeraseindole thio-barbituric acid analogsITBA analogsmachine learningMLQSARquantitative structure-activity relationshipTLStranslesion DNA synthesis

Identifiers

PMID41340396
PMCPMC12675996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.